| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Voksentoppen Asthma and Allergy Centre, National Hospital of Norway, and 2 Dept of Paediatrics, Division of Woman and Child, Ulleval University Hospital, Oslo, Norway
CORRESPONDENCE: C.S. Devulapalli, Voksentoppen BKL, National Hospital of Norway, Ullveien14, N-0791 Oslo, Norway. Fax: 47 22136505. E-mail:c.s.devulapalli@medisin.uio.no
Keywords: Asthma, bronchial obstruction, children, inhaled corticosteroids, tidal flow/volume loops, wheezy infants
Received: August 20, 2003
Accepted January 5, 2004
The ECA study was supported by grants from the Norwegian Research Council. Astra Zeneca, Oslo, Norway has provided an educational grant for the first author.
The objectives of the present study were to determine the use of inhaled corticosteroids (ICS) for treating recurrent bronchial obstruction (rBO) in young children up to 2 yrs of age and to assess possible modifying effects of ICS on lung function in young children with rBO. From an observational, noninterventional birth cohort of 3,754 newborn children (3,697 with complete questionnaire data by 2 yrs of age), 306 children with documented rBO by age 2 yrs (cases) were identified along with 306 matched controls.
Two tidal flow/volume measurements were taken, one at presentation of disease (children were steroid naïve) and one at 2 yrs of age (mean age 11.2 and 25.6 months, respectively), from: 21 cases who subsequently received ICS (ICS+); 33 who did not (ICS–); and in 15 controls. The mean±sd duration of ICS treatment was 10.3±6.5 months. The main outcomes were treatment with ICS and baseline ratio of time to peak expiratory flow/total expiratory time (tPTEF/tE).
From the entire cohort, 77 children (2.1%) and 21% of children with rBO had received ICS by 2 yrs of age. Baseline tPTEF/tE was significantly lower at the first visit only in ICS+ as compared to ICS– subjects, as well as in ICS+ and ICS- as compared to controls. The mean difference in baseline tPTEF/tE from first to second visit was borderline statistically significant in the ICS+ group only and correlated significantly with duration of ICS treatment.
The present observational cohort study demonstrated that one-fifth of young children with recurrent bronchial obstruction had received inhaled corticosteroids. Early inhaled corticosteroid treatment improved lung function by age 2 yrs, mostly in those with the longest duration of treatment.
This article has been cited by other articles:
|
|
 |
|
  C S Devulapalli, K C L Carlsen, G Haland, M C Munthe-Kaas, M Pettersen, P Mowinckel, and K-H Carlsen Severity of obstructive airways disease by age 2 years predicts asthma at 10 years of age Thorax, January 1, 2008; 63(1): 8 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Teper, C. D. Kofman, G. A. Szulman, S. M. Vidaurreta, and A. F. Maffey Fluticasone Improves Pulmonary Function in Children under 2 Years Old with Risk Factors for Asthma Am. J. Respir. Crit. Care Med., March 15, 2005; 171(6): 587 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Silverman Inhaled corticosteroids and the growth of lung function in children Eur. Respir. J., June 1, 2004; 23(6): 795 - 796. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
